Table 2.
Slope, intercept, Pearson correlation coefficient, and predicted LDL-C values based on simple linear regression of LDL-C on apoB at baseline (ie, in drug-naïve patients) and endpoint (ie, last post-baseline on-treatment measurement)
| Na | Slope | Intercept | Pearson correlation coefficient (95% CI) | Predictedb LDL-C value (95% CI) given apoB of 0.8 g/L |
Predictedb LDL-C value (95% CI) given apoB of 0.9 g/L |
|
|---|---|---|---|---|---|---|
| Baseline (ie, in drug-naïve patients) | ||||||
| Pooled across treatment groups | 1,233 | 1.29 | 2.04 | 0.64 (0.61–0.68) | 3.07 (3.01–3.13) | 3.19 (3.14–3.25) |
| TG <2.26 mmol/L | 983 | 1.63 | 1.62 | 0.73 (0.70–0.75) | 2.92 (2.86–2.98) | 3.08 (3.03–3.13) |
| TG ≥2.26 mmol/L | 250 | 1.42 | 1.61 | 0.65 (0.57–0.72) | 2.74 (2.56–2.92) | 2.88 (2.72–3.04) |
| ERN/LRPT | 155 | 1.01 | 2.40 | 0.53 (0.41–0.64) | 3.21 (3.04–3.38) | 3.31 (3.16–3.46) |
| TG <2.26 mmol/L | 121 | 1.37 | 1.96 | 0.66 (0.55–0.75) | 3.05 (2.88–3.23) | 3.19 (3.04–3.34) |
| TG ≥2.26 mmol/L | 34 | 1.17 | 1.93 | 0.52 (0.21–0.72) | 2.86 (2.28–3.44) | 2.98 (2.47–3.49) |
| Pooled SIMVA | 561 | 1.40 | 1.88 | 0.70 (0.65–0.74) | 3.00 (2.91–3.08) | 3.14 (3.06–3.21) |
| TG <2.26 mmol/L | 444 | 1.73 | 1.46 | 0.77 (0.73–0.81) | 2.85 (2.76–2.93) | 3.02 (2.95–3.09) |
| TG ≥2.26 mmol/L | 117 | 1.34 | 1.77 | 0.65 (0.53–0.75) | 2.84 (2.60–3.09) | 2.98 (2.76–3.19) |
| Pooled ERN/LRPT + SIMVA | 517 | 1.23 | 2.13 | 0.61 (0.55–0.66) | 3.11 (3.02–3.21) | 3.24 (3.15–3.32) |
| TG <2.26 mmol/L | 418 | 1.56 | 1.72 | 0.69 (0.63–0.73) | 2.97 (2.86–3.07) | 3.12 (3.03–3.21) |
| TG ≥2.26 mmol/L | 99 | 1.58 | 1.30 | 0.69 (0.57–0.78) | 2.57 (2.27–2.87) | 2.73 (2.46–2.99) |
| Endpoint (ie, in drug-treated patients) | ||||||
| ERN/LRPT | 160 | 2.58 | 0.11 | 0.88 (0.84–0.91) | 2.18 (2.08–2.29) | 2.44 (2.35–2.53) |
| TG <2.26 mmol/L | 124 | 2.81 | −0.11 | 0.91 (0.87–0.94) | 2.14 (2.04–2.24) | 2.42 (2.34–2.50) |
| TG ≥2.26 mmol/L | 36 | 2.42 | 0.18 | 0.77 (0.59–0.88) | 2.12 (1.70–2.54) | 2.36 (2.00–2.72) |
| Pooled SIMVA | 564 | 2.64 | −0.26 | 0.87 (0.85–0.89) | 1.85 (1.80–1.89) | 2.11 (2.08–2.14) |
| TG <2.26 mmol/L | 477 | 2.83 | −0.40 | 0.89 (0.87–0.91) | 1.87 (1.83–1.91) | 2.15 (2.12–2.18) |
| TG ≥2.26 mmol/L | 117 | 2.82 | −0.71 | 0.88 (0.84–0.92) | 1.54 (1.41–1.67) | 1.82 (1.72–1.93) |
| Pooled ERN/LRPT + SIMVA | 519 | 2.36 | 0.00 | 0.83 (0.80–0.86) | 1.89 (1.84–1.93) | 2.12 (2.08–2.17) |
| TG <2.26 mmol/L | 419 | 2.31 | 0.07 | 0.80 (0.76–0.83) | 1.91 (1.86–1.96) | 2.14 (2.09–2.20) |
| TG ≥2.26 mmol/L | 100 | 2.69 | −0.43 | 0.94 (0.92–0.96) | 1.73 (1.65–1.80) | 2.00 (1.93–2.06) |
Notes:
a
Number of patients with paired apoB and LDL-C measurements
b
predicted LDL-C value (mmol/L) assuming apoB value of 0.8 or 0.9 g/L.
Abbreviations: apoB, apolipoprotein B; CI, confidence interval; ERN, extended-release niacin; LDL-C, low-density lipoprotein cholesterol; LRPT, laropiprant; SD, standard deviation; SIMVA, simvastatin; TG, baseline triglyceride value.